|
|
|
|
| LEADER |
07534cam a22007097i 4500 |
| 001 |
MUB03000005291 |
| 003 |
CZ BrMU |
| 005 |
20230313130825.0 |
| 008 |
180803t20172017sz |||||o|||||||||||eng d |
| STA |
|
|
|a EIZ
|b 333
|c EBSCO trvale nakupy
|d 2018-07-31
|
| 020 |
|
|
|a 978-3-319-33703-6
|q (eBook)
|
| 035 |
|
|
|a (OCoLC)ocn975370122
|
| 035 |
|
|
|a (OCoLC)975370122
|z (OCoLC)974694890
|z (OCoLC)974750486
|z (OCoLC)974969034
|z (OCoLC)975045597
|z (OCoLC)975108538
|z (OCoLC)975224543
|z (OCoLC)975461206
|z (OCoLC)984854983
|z (OCoLC)993545473
|z (OCoLC)993688992
|z (OCoLC)999519273
|z (OCoLC)1005800469
|z (OCoLC)1011851185
|
| 040 |
|
|
|a GW5XE
|b cze
|e rda
|c GW5XE
|d N$T
|d EBLCP
|d YDX
|d UAB
|d DKU
|d OCLCF
|d IOG
|d AZU
|d UPM
|d MERER
|d ESU
|d OCLCQ
|d JBG
|d IAD
|d ICW
|d ICN
|d VT2
|d COO
|d OTZ
|d OCLCQ
|d OCLCO
|d OCLCA
|d U3W
|d OCLCA
|d GBVCP
|d OCLCO
|d CAUOI
|d MMU
|d OCLCO
|d OCL
|d OCLCO
|d BOD034
|
| 072 |
|
7 |
|a 616
|x Patologie. Klinická medicína
|2 Konspekt
|9 14
|
| 080 |
|
|
|a 616.34-002
|2 MRF
|
| 080 |
|
|
|a 616.34-002
|2 MRF
|
| 080 |
|
|
|a 616-036.22
|2 MRF
|
| 080 |
|
|
|a 616-092.19:57
|2 MRF
|
| 080 |
|
|
|a 616-07
|2 MRF
|
| 080 |
|
|
|a 616-08
|2 MRF
|
| 080 |
|
|
|a 616-073
|2 MRF
|
| 245 |
0 |
0 |
|a Crohn's disease and ulcerative colitis :
|b from epidemiology and immunobiology to a rational diagnostic and therapeutic approach /
|c Daniel C. Baumgart, editor
|
| 250 |
|
|
|a Second edition
|
| 264 |
|
1 |
|a Cham :
|b Springer,
|c [2017]
|
| 264 |
|
4 |
|c ©2017
|
| 300 |
|
|
|a 1 online zdroj (xx, 695 stran) :
|b ilustrace, mapy
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a počítač
|b c
|2 rdamedia
|
| 338 |
|
|
|a online zdroj
|b cr
|2 rdacarrier
|
| 505 |
0 |
|
|a Part I: Epidemiology. Environmental factors in the epidemiology of inflammatory bowel disease -- Part II: Immunobiology. Role of the intestinal immune system in health -- Understanding the epithelial barrier in IBD -- Intestinal microbiology and ecology in Crohn's disease and ulcerative colitis -- The immune system in IBD: antimicrobial peptides -- Vascular responses to intestinal inflammation -- Immunobiology of human dendritic cells in inflammatory bowel disease -- Immunobiology of T-cells in inflammatory bowel disease -- Immunobiology of B cells in inflammatory bowel disease -- Immune cells: monocytes and macrophages -- Immune functions of epithelial cells in inflammatory bowel disease -- Autophagy and endoplasmic reticulum stress -- Matrix metalloproteinases -- Paradigm of T cell differentiation in IBD -- Mouse models of chronic intestinal inflammation: characterization and use in pharmacological intervention studies ---Stem cells and organoids to study epithelial cell biology in IBD -- Part III: Diagnostic approach. Enhanced endoscopy -- Magnetic resonance enterography -- Computed tomography enterography and inflammatory bowel disease -- Ultrasound in inflammatory bowel disease -- Laboratory evaluation, including novel diagnostic markers -- Pathology of inflammatory bowel disease -- Objective assessment of clinical disease activity -- Objective assessment of endoscopic disease activity and mucosal healing -- Evaluation of quality of life in Crohn's disease and ulcerative colitis: what is health-related quality of life? -- Evaluation of health economics in inflammatory bowel disease -- Part IV: therapy: Crohn's disease. The natural history of inflammatory bowel disease -- Conventional medical management of Crohn's disease: sulfasalazine -- Steroid therapy for Crohn's disease -- Thiopurines in Crohn's disease -- Conventional medical management of Crohn's disease: methotrexate ---Adalimumab for the treatment of Crohn's disease -- Biologic therapy of Crohn's disease: certolizumab -- Biologic therapy for Crohn's disease: infliximab -- Briakinumab and ustekinumab: anti-p40 antibodies for inflammatory bowel disease treatment -- Biological therapy of Crohn's disease: natalizumab, vedolizumab, and anti-madCAM -- Optimal management of fistulizing Crohn's disease -- Part V: Therapy: ulcerative colitis. Sulfasalazine and 5-aminosalicylates for ulcerative colitis -- Conventional therapy of ulcerative colitis: corticosteroids -- Medical management of ulcerative colitis: conventional therapy--azathioprine -- Calcineurin inhibitors in ulcerative colitis -- Biologic therapy in moderate-to-severe ulcerative colitis: infliximab -- Biologic therapy of ulcerative colitis: adalimumab -- Biologic therapy of ulcerative colitis: golimumab -- Biologic therapy of ulcerative colitis: natalizumab, vedolizumab, etrolizumab (rHUMab beta 7), anti-MAdCAM ---Probiotics, prebiotics, and antibiotics in IBD -- Biosimilars in the treatment of inflammatory bowel disease -- Step-up vs. Top-down approach in Crohn's disease -- Leukocytapheresis therapy of inflammatory bowel disease -- Surgical management of Crohn's disease and ulcerative colitis -- Part VI: Extraintestinal manifestations. Extraintestinal manifestations: autoimmune hepatitis -- Primary sclerosing cholangitis -- Autoimmune pancreatitis and other organ involvement -- Cutaneous and oral manifestations of inflammatory bowel disease -- Arthritis, arthropathy, and osteoporosis in inflammatory bowel disease -- Part VII: Nutrition. Nutrition in inflammatory bowel disease -- Part VIII: Pregnancy, family planning and pediatric aspects. Pregnancy and fertility in inflammatory bowel disease -- Pediatric aspects of inflammatory bowel disease -- Part IX: Surveillance and prevention. Management and prevention of infectious diseases in IBD patients ---Incidence of cancer and screening in inflammatory bowel disease -- Inflammatory bowel diseases: how to identify high-risk patients -- Part X: Patient perspective and resources. Patient perspective on inflammatory bowel disease -- Patient resources in inflammatory bowel disease
|
| 533 |
|
|
|a Elektronická reprodukce.
|n Přístup pouze pro oprávněné uživatele
|
| 650 |
0 |
7 |
|a Crohnova nemoc
|7 ph117486
|2 czenas
|
| 650 |
0 |
7 |
|a ulcerózní kolitida
|7 ph126871
|2 czenas
|
| 650 |
0 |
7 |
|a epidemiologie
|7 ph114481
|2 czenas
|
| 650 |
0 |
7 |
|a imunobiologie
|7 ph564288
|2 czenas
|
| 650 |
0 |
7 |
|a diagnostika (lékařství)
|7 ph114312
|2 czenas
|
| 650 |
0 |
7 |
|a terapie
|7 ph116435
|2 czenas
|
| 650 |
0 |
7 |
|a diagnostické zobrazovací metody
|7 ph134757
|2 czenas
|
| 650 |
0 |
9 |
|a Crohn's disease
|2 eczenas
|
| 650 |
0 |
9 |
|a ulcerative colitis
|2 eczenas
|
| 650 |
0 |
9 |
|a epidemiology
|2 eczenas
|
| 650 |
0 |
9 |
|a immunobiology
|2 eczenas
|
| 650 |
0 |
9 |
|a medical diagnostics
|2 eczenas
|
| 650 |
0 |
9 |
|a therapy
|2 eczenas
|
| 650 |
0 |
9 |
|a diagnostic imaging methods
|2 eczenas
|
| 655 |
|
7 |
|a e-knihy online
|2 CZ-BrMU
|
| 655 |
|
9 |
|a e-books online
|2 eCZ-BrMU
|
| 700 |
1 |
|
|a Baumgart, Daniel C.
|4 edt
|
| 776 |
0 |
8 |
|i Tištěná verze:
|t Crohn's disease and ulcerative colitis : from epidemiology and immunobiology to a rational diagnostic and therapeutic approach.
|z 978-3-319-33701-2
|
| 856 |
4 |
1 |
|z Elektronická verze přístupná pouze pro studenty a pracovníky MU
|u https://ezproxy.muni.cz/login?url=https://search.ebscohost.com/login.aspx?authtype=ip&custid=s8431878&lang=cs&profile=eds&direct=true&db=nlebk&AN=1219726
|
| CAT |
|
|
|c 20180803
|l MUB03
|h 1520
|
| CAT |
|
|
|c 20190222
|l MUB03
|h 1623
|
| CAT |
|
|
|c 20190222
|l MUB03
|h 1659
|
| CAT |
|
|
|c 20210421
|l MUB03
|h 2124
|
| CAT |
|
|
|c 20210421
|l MUB03
|h 2208
|
| CAT |
|
|
|a PLISKOVA
|b 02
|c 20230313
|l MUB03
|h 1133
|
| CAT |
|
|
|a PLISKOVA
|b 02
|c 20230313
|l MUB03
|h 1308
|
| 995 |
|
|
|a eBook
|
| 994 |
- |
1 |
|l MUB03
|l MUB03
|m EBOOK
|1 KUK
|a Knihovna univ. kampusu
|2 EBKUK
|b e-knihy (trvalý nákup)
|5 3284L00569
|8 20180801
|f 83
|f Dálkově přístupná
|s kup
|
| AVA |
|
|
|a MED50
|b KUK
|c e-knihy (trvalý nákup)
|e available
|t K dispozici
|f 1
|g 0
|h N
|i 0
|j EBKUK
|
